AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019) - Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; et al.